Repare Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences for its RP-3467 program, generating up to $30 million and increasing the estimated cash payout to shareholders in its pending acquisition by Xeno.
Repare Therapeutics announced the resignation of its Chief Scientific Officer, Michael Zinda, effective December 31, 2025, coinciding with an update on its proposed acquisition by XenoTherapeutics.
Repare Therapeutics Inc. shareholders will vote on a proposed acquisition by Xeno Acquisition Corp. for cash and contingent value rights, or a voluntary liquidation.
Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., with shareholders receiving cash and contingent value rights.
Repare Therapeutics announced significant shareholder support, totaling approximately 40% of outstanding shares, for its proposed acquisition by XenoTherapeutics, Inc.
Repare Therapeutics Inc. has entered into an Arrangement Agreement to be acquired by Xeno Acquisition Corp. for an estimated $1.82 per share cash plus contingent value rights.
Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc. for an estimated US$1.82 per share plus one Contingent Value Right.
Repare Therapeutics Inc. will hold its annual shareholder meeting on June 17, 2025, to elect directors, approve executive compensation, and appoint an independent accounting firm.
Repare Therapeutics will hold its annual shareholder meeting virtually on June 17, 2025, to vote on director elections, executive compensation, and auditor appointment.
Repare Therapeutics Inc. will hold its annual meeting of shareholders on June 17, 2024, to elect directors, approve executive compensation, and appoint an independent accounting firm.
Repare Therapeutics has scheduled its Annual Meeting of Shareholders for June 17, 2024, to address director elections, executive compensation, and the appointment of an independent accounting firm.